International Journal of Environmental Sciences
ISSN: 2229-7359
Vol. 11 No. 24s, 2025
https://theaspd.com/index.php

Biogeochemistry Of Pharmaceutical Compounds In Aquatic Ecosystems

Abhishek Anand[1], Mithul V Mammen[1], Amit Kumar[2*]
[1]Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India -244001
[2]Shri Venkateshwara School of Pharmacy, Shri Venkateshwara University, Rajabpur, Gajraula, Amroha, Uttar Pradesh, India

Abstract
Pharmaceutical compounds, including antibiotics, analgesics, and hormones, have emerged as significant contaminants in aquatic ecosystems due to their widespread use and persistence. This review synthesizes current knowledge on the biogeochemical dynamics of these compounds, focusing on their sources, fate, ecological impacts, and management in aquatic environments. Primary sources, such as wastewater treatment plant effluents, agricultural runoff, and improper disposal, introduce pharmaceuticals into rivers, lakes, wetlands, and oceans. Biogeochemical processes, including adsorption to sediments, microbial and abiotic degradation, and bioaccumulation in aquatic biota, govern their transport and transformation. These processes influence nutrient cycling and ecosystem functions, with sublethal effects on fish, invertebrates, and algae, alongside broader consequences like biodiversity loss and antibiotic resistance gene proliferation. Case studies from systems like the Danube, Lake Geneva, and the Baltic Sea highlight spatial and temporal variations in pharmaceutical loads, emphasizing regional disparities between developed and developing nations. Mitigation strategies, including advanced treatment technologies (e.g., ozonation, activated carbon), regulatory frameworks, and sustainable practices like green pharmacy, offer solutions to reduce environmental impacts. However, challenges such as mixture toxicities, long-term ecological effects, and climate interactions remain. This review underscores the need for integrated monitoring, interdisciplinary research, and global collaboration to address pharmaceutical pollution, providing a comprehensive framework for understanding its biogeochemical and ecological implications in aquatic ecosystems.

1. INTRODUCTION

1.1 Overview of Biogeochemistry in Environmental Contexts

Biogeochemistry examines the intricate interplay of chemical, biological, and geological processes that govern the cycling of elements and compounds within ecosystems [1]. This interdisciplinary field integrates principles from chemistry, biology, and geology to elucidate how substances, such as nutrients and pollutants, move through environmental compartments like air, water, soil, and biota. Key cycles, including those of carbon, nitrogen, and trace elements, are driven by processes such as microbial metabolism, chemical transformations (e.g., oxidation, reduction), and physical transport mechanisms (e.g., advection, diffusion) [2]. In the context of pollutants, biogeochemistry provides a framework to understand their fate, transformation, and impacts across ecosystems. Pharmaceuticals, as emerging contaminants, are particularly relevant due to their bioactive nature and widespread environmental presence [3]. These compounds can alter microbial communities, disrupt nutrient cycling, and interact with geological matrices, such as sediments, affecting ecosystem functions [4]. For instance, antibiotics may inhibit nitrogen-fixing bacteria, thereby influencing the nitrogen cycle in aquatic systems [5]. The study of pharmaceutical biogeochemistry is thus critical for assessing environmental risks and predicting long-term ecological consequences in a rapidly changing world.

1.2 Pharmaceutical Compounds as Emerging Contaminants

Pharmaceuticals, encompassing a diverse range of compounds such as antibiotics, analgesics, antidepressants, and hormones, are integral to modern healthcare, with global consumption estimated in millions of tons annually [6]. These compounds, designed for therapeutic purposes, include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, antibiotics like ciprofloxacin, and synthetic hormones like ethinylestradiol, each with distinct chemical properties influencing their environmental behavior [7]. The rise in pharmaceutical use, driven by population growth, aging demographics, and increased access to healthcare, has led to significant environmental release [8]. Unlike traditional pollutants, pharmaceuticals are biologically active at low concentrations (ng/L to µg/L), posing unique challenges due to their persistence and potential

for ecological disruption [9]. For example, studies have detected diclofenac in surface waters globally, with concentrations reaching up to 1.2 µg/L in some regions, highlighting their ubiquity [10]. Primary release pathways include human excretion (via urine and feces), improper disposal of unused medications, and effluents from pharmaceutical manufacturing [11]. Conventional wastewater treatment plants (WWTPs) often achieve only partial removal, allowing compounds like carbamazepine to persist in effluents discharged into aquatic environments [12]. The continuous input and bioactive properties of these compounds necessitate a detailed understanding of their environmental fate and impacts.

1.3 Significance in Aquatic Ecosystems

Aquatic ecosystems, including rivers, lakes, wetlands, and oceans, are critical arenas for studying pharmaceutical contamination due to their role as sinks and conduits in global biogeochemical cycles [13]. These systems are highly vulnerable to pollution because of their connectivity, receiving inputs from terrestrial sources via runoff, groundwater discharge, and atmospheric deposition [14]. Rivers, for instance, transport pharmaceuticals from urban and agricultural areas to downstream ecosystems, while wetlands may act as natural filters through processes like sorption and biodegradation [15]. The biogeochemical significance of aquatic systems lies in their capacity to mediate the cycling of nutrients and contaminants, influencing ecosystem services such as water purification, nutrient retention, and biodiversity support [16]. Pharmaceuticals can disrupt these functions; for example, antibiotics may alter microbial communities critical to denitrification, affecting nitrogen cycling [17]. Moreover, the persistence of pharmaceuticals in aquatic environments, coupled with their potential to bioaccumulate in organisms like fish, amplifies their ecological impact [18]. Understanding these dynamics is essential for predicting how pharmaceuticals interact with aquatic biogeochemical processes and for safeguarding ecosystem health.



Figure 1: Conceptual Diagram of Pharmaceutical Pathways in Aquatic Ecosystems, illustrating sources (e.g., WWTPs, agriculture), transport (e.g., runoff, groundwater), and sinks (e.g., sediments, biota).

1.4 Objectives and Scope of the Review

This review aims to synthesize current knowledge on the biogeochemical fate, ecological impacts, and management strategies for pharmaceutical compounds in aquatic ecosystems, adopting an interdisciplinary approach that bridges environmental chemistry, biology, and ecology [19]. It explores the sources and pathways of pharmaceutical entry, key biogeochemical processes (e.g., adsorption, degradation, bioaccumulation), and their ecological and human health implications, supported by case studies and empirical data. The review also evaluates mitigation strategies, including advanced treatment technologies and policy frameworks, to address pharmaceutical pollution [20]. By integrating diverse perspectives, this work seeks to provide a comprehensive understanding of pharmaceutical biogeochemistry and inform sustainable environmental management practices.

2. Sources and Pathways of Pharmaceutical Entry into Aquatic Ecosystems

2.1 Primary Sources: Wastewater Treatment Plants and Effluents

Wastewater treatment plants (WWTPs) are the primary conduits for pharmaceutical entry into aquatic ecosystems, as conventional treatment processes often achieve incomplete removal of these compounds [21]. Pharmaceuticals such as ibuprofen, carbamazepine, and sulfamethoxazole are frequently detected in WWTP effluents due to their high usage and resistance to standard treatment methods like activated sludge [22]. Global estimates suggest that WWTPs discharge billions of liters of treated wastewater daily, contributing significant pharmaceutical loads to surface waters [23]. For instance, a European study reported diclofenac in 90% of WWTP effluents at concentrations up to 1.2 μg/L, with removal efficiencies often below 50% [24]. Factors such as compound polarity, solubility, and treatment plant design influence removal rates, with persistent compounds like carbamazepine showing removal efficiencies as low as 10% [25]. Urban WWTPs, particularly in densely populated regions, amplify this issue due to high influent concentrations from domestic sources [26]. The continuous discharge of effluents creates chronic exposure scenarios in receiving waters, necessitating advanced treatment technologies to mitigate pharmaceutical pollution [27].

2.2 Agricultural and Veterinary Contributions

Agricultural and veterinary practices significantly contribute to pharmaceutical contamination through runoff and leaching from livestock operations and aquaculture [28]. Antibiotics, such as tetracyclines and sulfonamides, are widely used in animal husbandry to treat infections and promote growth, with substantial fractions excreted unchanged in manure [29]. When manure is applied to fields, rainfall can mobilize these compounds into surface waters or groundwater via soil leaching, with studies detecting tetracycline residues in streams at concentrations up to 0.5 μg/L [30]. Aquaculture further exacerbates this issue, as antibiotics are directly introduced into aquatic environments during fish farming [31]. For example, oxytetracycline used in shrimp farming has been detected in coastal waters, impacting local ecosystems [32]. Soil properties, such as organic matter content and pH, influence the mobility of these compounds, with sandy soils facilitating greater transport to water bodies [33]. These agricultural inputs highlight the need for sustainable management practices to reduce pharmaceutical runoff.

2.3 Other Anthropogenic Pathways

Beyond WWTPs and agriculture, other anthropogenic sources contribute significantly to pharmaceutical pollution. Hospital effluents, containing high concentrations of antibiotics, cytostatics, and contrast agents, are often discharged into municipal sewer systems with limited pretreatment [34]. Improper disposal of unused or expired medications, such as flushing drugs down toilets, further introduces compounds like analgesics and antidepressants into aquatic systems [35]. Industrial effluents from pharmaceutical manufacturing plants are another critical source, with studies reporting concentrations of active pharmaceutical ingredients (APIs) as high as 100 μg/L in rivers near production facilities in developing nations [36]. Urban runoff, particularly during heavy rainfall events, exacerbates contamination by mobilizing pharmaceuticals from combined sewer overflows and stormwater [37]. These diverse pathways underscore the complexity of managing pharmaceutical inputs and the need for targeted interventions at multiple stages of the waste stream.

2.4 Natural and Indirect Inputs

Natural and indirect pathways also contribute to pharmaceutical presence in aquatic ecosystems, though to a lesser extent. Atmospheric deposition, where pharmaceuticals volatilized from WWTPs or landfills settle into water bodies, has been documented for compounds like ibuprofen [38]. Wildlife excretion, particularly from animals exposed to veterinary drugs, introduces trace amounts of pharmaceuticals into aquatic environments [39]. Additionally, microplastics have emerged as vectors for pharmaceutical transport, adsorbing compounds like fluoroquinolones and releasing them in aquatic systems under changing environmental conditions [40]. These indirect inputs, while less quantified, add to the cumulative load of pharmaceuticals and complicate source attribution, requiring advanced monitoring techniques to assess their significance [41].

Table 1: Major Sources and Estimated Contributions of Pharmaceuticals to Aquatic Systems

Source	Estimated Global Input (tons/year)	Key Compounds Detected
Wastewater Treatment Plants (WWTPs)	10,000	Diclofenac, Ibuprofen, Carbamazepine, Sulfamethoxazole

Agriculture / Livestock	5,000	Tetracycline, Oxytetracycline, Sulfonamides
Hospitals	1,000	Ciprofloxacin, Amoxicillin, Iodinated Contrast Media
Urban Runoff / Domestic Sources	2,000	Fluoxetine, Atenolol, Metformin
Industrial Effluents	500	Paracetamol, Diclofenac, APIs

3. Biogeochemical Processes Governing Fate and Transport

3.1 Adsorption and Partitioning in Sediments and Soils

Adsorption and partitioning in sediments and soils are critical processes determining the fate of pharmaceuticals in aquatic ecosystems [42]. Sorption mechanisms, including hydrophobic interactions, ion exchange, and hydrogen bonding, govern the binding of compounds like fluoroquinolones to environmental matrices [43]. Partition coefficients, such as Kd (distribution coefficient) and Koc (organic carbon-water partition coefficient), quantify these interactions, with fluoroquinolones exhibiting high Koc values due to their affinity for organic matter [44]. Organic matter content and clay minerals in sediments enhance sorption, reducing bioavailability but creating long-term reservoirs of contaminants [45]. For instance, studies show that ciprofloxacin strongly adsorbs to river sediments, with Kd values ranging from 100 to 1,000 L/kg [46]. Environmental factors like pH and ionic strength further modulate sorption, with cationic pharmaceuticals binding more readily under acidic conditions [47]. These processes influence the mobility and persistence of pharmaceuticals, affecting their availability for degradation or uptake.

3.2 Degradation Pathways: Biotic and Abiotic

Degradation pathways, both biotic and abiotic, play a pivotal role in the transformation of pharmaceuticals in aquatic environments [48]. Microbial biodegradation, mediated by bacteria in biofilms or sediments, breaks down compounds like ibuprofen into less harmful metabolites, though rates vary widely [49]. For example, ibuprofen has a half-life of days to weeks in aerobic conditions but persists longer in anoxic environments [50]. Abiotic processes, including photodegradation in surface waters and hydrolysis, further degrade pharmaceuticals, with compounds like diclofenac undergoing rapid photolysis under sunlight (half-life ~hours) [51]. Transformation products, such as diclofenac metabolites, may retain bioactivity, complicating risk assessments [52]. Kinetic studies provide critical data, with half-lives ranging from hours (e.g., diclofenac under UV) to months (e.g., carbamazepine in groundwater) [53]. These processes collectively determine the environmental persistence of pharmaceuticals and their potential to impact ecosystems.

3.3 Bioaccumulation and Biomagnification

Bioaccumulation and biomagnification govern the uptake and concentration of pharmaceuticals in aquatic organisms [54]. Compounds like fluoxetine are absorbed by fish and invertebrates via gills or diet, with bioconcentration factors (BCF) indicating accumulation potential (e.g., BCF of fluoxetine ~100-1,000) [55]. Lipophilic compounds accumulate in fatty tissues, while polar compounds may concentrate in specific organs like the liver [56]. Trophic transfer in food webs can lead to biomagnification, with higher concentrations observed in predators like piscivorous fish [57]. For instance, studies have detected ethinylestradiol in fish at levels sufficient to cause endocrine disruption, impacting reproduction [58]. These processes highlight the risk of pharmaceuticals moving through aquatic ecosystems, affecting biodiversity and food web dynamics.

3.4 Transport Dynamics: Hydrological and Geochemical Influences

Transport dynamics, driven by hydrological and geochemical processes, control the movement of pharmaceuticals in aquatic systems [59]. Advection and diffusion in rivers facilitate downstream transport, while groundwater-surface water interactions introduce pharmaceuticals into aquifers [60]. Models like fugacity and mass balance predict transport behavior, with studies showing rapid movement of ibuprofen in high-flow rivers [61]. Geochemical factors, such as redox conditions and pH, influence transport by altering compound speciation and solubility [62]. For example, sulfonamides exhibit greater mobility in alkaline waters due to increased solubility [63]. These dynamics underscore the need for integrated modeling to predict pharmaceutical distribution across diverse aquatic environments.

Table 2: Physicochemical Properties and Fate Parameters of Key Pharmaceuticals

Compound	Log Kow	Water Solubility (mg/L)	Half-Life in Water (days)	Bioconcentration Factor (BCF)
Ibuprofen	3.97	21	15–20	10–50
Carbamazepine	2.45	18	100–200	1–10
Diclofenac	4.51	2.37	1–5 (photodegradation)	50–100
Ciprofloxacin	0.28	30,000	10–30	5–20
Ethinylestradiol	3.67	11.3	10–20	100–1,000

4. Ecological and Biological Impacts

4.1 Effects on Microbial Communities and Biogeochemical Cycles

Pharmaceuticals, particularly antibiotics, significantly impact microbial communities and biogeochemical cycles in aquatic ecosystems [64]. Antibiotics like tetracycline can inhibit nitrogen-fixing bacteria or denitrifying microbes, disrupting nitrogen cycling and reducing ecosystem productivity [65]. Metagenomic studies reveal shifts in microbial diversity, with antibiotic-resistant bacteria proliferating in contaminated waters, altering community structure [66]. These changes affect carbon and nutrient cycling, as microbes are key drivers of decomposition and nutrient transformation [67]. For instance, a study in a contaminated river showed a 30% reduction in denitrification rates due to antibiotic exposure [68].



Figure 2: Trophic Transfer and Ecological Impacts, a diagram illustrating pharmaceutical bioaccumulation in aquatic food webs (e.g., algae to fish to predators) and associated ecological effects.

4.2 Toxicity to Aquatic Organisms

Pharmaceuticals exert significant sublethal effects on aquatic organisms, impacting fish, invertebrates, and algae through chronic exposure at environmentally relevant concentrations [69]. Synthetic hormones, such as ethinylestradiol, are particularly concerning due to their endocrine-disrupting effects, with studies reporting feminization in male fish at concentrations as low as 5 ng/L, leading to altered reproductive behaviors and reduced population viability [70]. For example, ethinylestradiol exposure in zebrafish has been linked to decreased egg production, with an EC50 (effect concentration for 50% of the population) of approximately 10 ng/L for reproductive endpoints [71]. Invertebrates, such as daphnids, are sensitive to antidepressants like fluoxetine, which impair reproduction and mobility at concentrations around 100 ng/L [72]. Algae, critical primary producers, experience growth inhibition from antibiotics like erythromycin, with EC50 values ranging from 20 to 100 µg/L depending on species [73]. Chronic exposure data indicate that even trace levels of multiple pharmaceuticals can synergistically affect aquatic organisms, amplifying toxicity [74]. These effects underscore the need for comprehensive ecotoxicological assessments to understand the full scope of pharmaceutical impacts on aquatic biota [75].

4.3 Ecosystem-Level Consequences

The presence of pharmaceuticals in aquatic ecosystems can lead to broader ecological consequences, including biodiversity loss, proliferation of antibiotic resistance genes (ARGs), and cascading effects through food webs [76]. Antibiotics, such as ciprofloxacin, contribute to the spread of ARGs by exerting selective pressure on microbial communities, with studies detecting elevated ARG levels in rivers downstream of WWTPs [77]. This resistance can transfer to pathogenic bacteria, compromising ecosystem and human health [78]. Biodiversity loss is evident in systems exposed to high pharmaceutical loads, where sensitive species, such as certain macroinvertebrates, decline, altering community structures [79]. For instance, a study in a contaminated stream reported a 25% reduction in macroinvertebrate diversity due to chronic pharmaceutical exposure [80]. Cascading food web effects occur as pharmaceuticals bioaccumulate, with predators like fish and birds exhibiting behavioral changes or reduced fitness due to dietary uptake [81]. These ecosystem-level impacts disrupt services like nutrient cycling and food production, highlighting the urgency of addressing pharmaceutical pollution [82].

4.4 Human Health Implications via Aquatic Pathways

Pharmaceuticals in aquatic ecosystems pose indirect risks to human health through bioaccumulation in seafood and contamination of drinking water sources [83]. Compounds like fluoxetine and carbamazepine have been detected in fish consumed by humans, with concentrations in muscle tissue reaching up to 10 ng/g [84]. This bioaccumulation links to biogeochemical cycles, as pharmaceuticals partition into biota from water and sediments [85]. Drinking water sources are also affected, with trace levels of pharmaceuticals (e.g., 1-100 ng/L) detected in treated water supplies, raising concerns about long-term exposure [86]. For example, a study found atenolol in groundwater used for drinking, highlighting the role of hydrological transport in contamination [87]. While current concentrations are below acute toxicity thresholds, chronic exposure to mixtures of pharmaceuticals may pose risks, particularly for vulnerable populations [88]. These pathways emphasize the need to integrate biogeochemical insights into

5. Case Studies and Empirical Evidence

5.1 Riverine Systems: The Danube or Mississippi as Examples

Riverine systems are critical for studying pharmaceutical contamination due to their role as transport pathways and biogeochemical hotspots [89]. The Danube River, for instance, exhibits significant pharmaceutical loads, with monitoring data showing carbamazepine concentrations up to 200 ng/L in urban reaches [90]. Seasonal variations, driven by flow rates and dilution, influence concentrations, with higher levels during low-flow summer periods [91]. Similarly, the Mississippi River shows detectable levels of ibuprofen and sulfamethoxazole, with concentrations peaking near agricultural inputs [92]. These rivers serve as biogeochemical hotspots where oxic-anoxic interfaces in sediments enhance microbial transformation of pharmaceuticals [93]. Such data highlight the dynamic interplay of hydrological and geochemical factors in riverine contamination.

5.2 Lacustrine and Wetland Ecosystems

Lakes and wetlands exhibit distinct pharmaceutical dynamics due to their longer residence times and natural attenuation capacities [94]. In Lake Geneva, persistent compounds like carbamazepine have been detected at stable concentrations (~50 ng/L), reflecting limited degradation in deep, cold waters [95]. Wetlands, conversely, act as natural filters, with studies showing up to 80% removal of ibuprofen through sorption and biodegradation in constructed wetlands [96]. The high organic matter content in wetland sediments enhances these processes, reducing pharmaceutical mobility [97]. These systems underscore the role of biogeochemical conditions in modulating contaminant fate, with wetlands offering potential for natural remediation.

5.3 Marine and Estuarine Environments

Marine and estuarine environments face pharmaceutical contamination through dilution and accumulation processes [98]. The Baltic Sea, for example, shows detectable levels of diclofenac (up to 10 ng/L) in coastal zones, with accumulation in sediments due to low water exchange [99]. Estuaries, as transition zones, experience variable concentrations driven by tidal mixing and riverine inputs [100]. Studies indicate that marine organisms, such as mussels, bioaccumulate pharmaceuticals, amplifying risks to coastal ecosystems [101]. These findings highlight the need to consider marine systems in pharmaceutical pollution assessments.

5.4 Global Hotspots and Comparative Analysis

Global hotspots of pharmaceutical contamination vary by region, reflecting differences in usage, infrastructure, and regulation [102]. In Asia, the Ganges River exhibits high concentrations of antibiotics (e.g., ciprofloxacin up to 1 µg/L) due to dense populations and limited wastewater treatment [103]. In contrast, European rivers like the Thames show lower concentrations but higher diversity of compounds due to advanced monitoring [104]. Comparative analyses reveal that developing regions face greater challenges due to inadequate treatment infrastructure, while developed regions benefit from stricter regulations [105]. These disparities underscore the need for global strategies to address pharmaceutical pollution.

Table 3: Case Study Data on Pharmaceutical Concentrations, comparing detected concentrations (e.g., ng/L) of key compounds across rivers, lakes, and marine systems, with study references.

Compound	Rivers (ng/L)	Lakes (ng/L)	Marine/Estuarine (ng/L)	Study References
Ibuprofen (NSAID)	1–10,000 (global rivers, high in Asia)	31,250 (Polish wastewater-influenced lakes)	77–805 (Costa Rican coastal waters)	Wilkinson et al. (2013) ; Gieburowska et al. (2022) ; Fabbri & Franzellitti (2016)
Diclofenac (NSAID)	258–1,398 (Apatalco River, Mexico)	Not reported	0.01–6,800 (global coastal waters)	Rivera-Jaimes et al. (2018) ; Miller et al. (2018)
Sulfamethoxazole (Antibiotic)	1–10,000 (global rivers)	Not reported	0.1–16.7 (offshore China, Pearl River Estuary)	Wilkinson et al. (2013) ; Miller et al. (2018)
Carbamazepine (Anticonvulsant)	3.5–1,400 (various European rivers)	Not reported	42–1,762 (Tejo Estuary, Portugal; mixture total)	Writer et al. (2012) ; Reid et al. (2021)
Ciprofloxacin (Antibiotic)	Up to 10,000,000 (high in Asian rivers)	Not reported	0.01–680 (global estuaries)	Wilkinson et al. (2013) ; Adedipe et al. (2024)
Erythromycin-H_2O (Antibiotic metabolite)	Up to 10,000 (global rivers)	Not reported	0.1–16.7 (Pearl River Estuary, China)	Wilkinson et al. (2013) ; Miller et al. (2018)
Naproxen (NSAID)	732–4,889 (Apatalco River, Mexico)	551,960 (Polish lakes)	0.01–680 (global coastal)	Rivera-Jaimes et al. (2018) ; Gieburowska et al. (2022) ; Miller et al. (2018)
Cyclophosphamide (Cytotoxic)	0.05–22,100 (global rivers)	Not reported	Not reported	Nassour et al. (2020)

6. Mitigation Strategies and Environmental Management

6.1 Advanced Treatment Technologies

Advanced treatment technologies are critical for reducing pharmaceutical pollution in aquatic ecosystems [106]. Ozonation effectively degrades compounds like diclofenac, achieving removal efficiencies of 90% or higher, though it may produce toxic byproducts [107]. Activated carbon adsorption is highly effective for hydrophobic compounds like carbamazepine, with removal rates up to 95% [108]. Membrane bioreactors combine biological degradation and filtration, removing up to 80% of antibiotics like sulfamethoxazole [109]. Emerging enzyme-based degradation, using laccases, shows promise for breaking down complex

pharmaceuticals [110]. These technologies, while effective, require high energy and cost inputs, necessitating optimization for widespread adoption [111].

6.2 Policy and Regulatory Frameworks

Regulatory frameworks play a vital role in managing pharmaceutical pollution [112]. The EU Water Framework Directive prioritizes monitoring of emerging contaminants, including pharmaceuticals, to assess ecological risks [113]. Similarly, U.S. EPA guidelines emphasize risk assessments for compounds like diclofenac, though specific regulations remain limited [114]. Harmonizing global standards and incorporating pharmaceuticals into water quality criteria are essential for effective management [115]. Public-private partnerships can further support regulatory implementation and compliance [116].

6.3 Sustainable Practices and Prevention

Preventive measures, such as green pharmacy and drug take-back programs, reduce pharmaceutical inputs at the source [117]. Green pharmacy promotes the design of environmentally benign drugs, minimizing persistence and toxicity [118]. Take-back programs, implemented in countries like Sweden, have reduced improper disposal by 30% [119]. Public awareness campaigns and eco-friendly prescribing practices further limit environmental release [120]. These strategies align with sustainable development goals, emphasizing proactive pollution prevention.

6.4 Monitoring and Modeling Tools

Advanced monitoring and modeling tools enhance the tracking of pharmaceutical fates [121]. Remote sensing and GIS map contamination hotspots, while predictive models like fugacity estimate transport and transformation [122]. For instance, models have predicted carbamazepine persistence in rivers with 85% accuracy [123]. Integrating these tools with real-time monitoring improves the ability to manage pharmaceutical pollution effectively [124].

7. CONCLUSION AND FUTURE RESEARCH DIRECTIONS

7.1 Synthesis of Key Findings

This review highlights the complex biogeochemical dynamics of pharmaceuticals in aquatic ecosystems, from their entry via WWTPs, agriculture, and other sources to their fate through adsorption, degradation, and bioaccumulation [125]. These compounds disrupt microbial communities, nutrient cycles, and aquatic biota, with cascading effects on ecosystems and human health [126]. Case studies and mitigation strategies underscore the urgency of addressing this global issue through interdisciplinary approaches [127].

7.2 Challenges and Knowledge Gaps

Significant challenges remain, including uncertainties in long-term ecological effects, interactions with climate change, and the toxicity of pharmaceutical mixtures [128]. Limited data on transformation products and their bioactivity further complicates risk assessments [129]. Developing regions, with high contamination levels, face additional barriers due to infrastructure limitations [130].

7.3 Recommendations for Future Work

Future research should prioritize integrated monitoring systems, leveraging advanced analytics and global collaboration to track pharmaceutical fates [131]. Interdisciplinary studies on mixture toxicities and climate interactions are critical, as is the development of cost-effective treatment technologies [132]. Global policy harmonization and public engagement will further support sustainable management of pharmaceutical pollution [133].

REFERENCES

[1] W. H. Schlesinger, *Biogeochemistry: An Analysis of Global Change*, 3rd ed. Amsterdam, The Netherlands: Elsevier, 2013.
[2] J. E. Andrews, P. Brimblecombe, T. D. Jickells, P. S. Liss, and B. J. Reid, *An Introduction to Environmental Chemistry*, 2nd ed. Oxford, UK: Blackwell Publishing, 2004.
[3] M. Petrovic, S. Gonzalez, and D. Barcelo, "Analysis and removal of emerging contaminants in wastewater and drinking water," *Trends Anal. Chem.*, vol. 22, no. 10, pp. 685–696, 2003.
[4] R. P. Schwarzenbach, B. I. Escher, K. Fenner, T. B. Hofstetter, C. A. Johnson, U. von Gunten, and B. Wehrli, "The challenge of micropollutants in aquatic systems," *Science*, vol. 313, no. 5790, pp. 1072–1077, 2006.
[5] J. L. Martinez, "Environmental pollution by antibiotics and by antibiotic resistance determinants," *Environ. Pollut.*, vol. 157, no. 11, pp. 2893–2902, 2009.
[6] D. G. J. Larsson, "Pollution from drug manufacturing: Review and perspectives," *Philos. Trans. R. Soc. B*, vol. 369, no. 1656, p. 20130571, 2014.

[7] T. Heberer, "Occurrence, fate, and removal of pharmaceutical residues in the aquatic environment: A review," *Toxicol. Lett.*, vol. 131, no. 1–2, pp. 5–17, 2002.
[8] K. Kümmerer, "Pharmaceuticals in the environment," *Annu. Rev. Environ. Resour.*, vol. 35, pp. 57–75, 2010.
[9] B. W. Brooks, "Fish on Prozac: Effect of serotonin reuptake inhibitors on aquatic ecosystems," *Environ. Sci. Technol.*, vol. 48, no. 20, pp. 11736–11741, 2014.
[10] V. Acuña, A. Ginebreda, J. Mor, M. Petrovic, S. Sabater, J. Sumpter, and D. Barcelo, "Balancing risks of pharmaceuticals in European rivers," *Environ. Int.*, vol. 80, pp. 1–10, 2015.
[11] B. Kasprzyk-Hordern, R. M. Dinsdale, and A. J. Guwy, "The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK," *Water Res.*, vol. 42, no. 13, pp. 3498–3518, 2008.
[12] J. B. Ellis, "Pharmaceutical and personal care products (PPCPs) in urban receiving waters," *Environ. Pollut.*, vol. 144, no. 1, pp. 184–189, 2006.
[13] R. Costanza, R. d'Arge, R. de Groot, S. Farber, M. Grasso, B. Hannon, K. Limburg, S. Naeem, R. V. O'Neill, J. Paruelo, R. G. Raskin, P. Sutton, and M. van den Belt, "The value of the world's ecosystem services and natural capital," *Nature*, vol. 387, no. 6630, pp. 253–260, 1997.
[14] J. P. Sumpter, "The ecotoxicology of pharmaceuticals," *Environ. Health Perspect.*, vol. 115, no. 1, pp. 155–160, 2007.
[15] K. Fent, A. A. Weston, and D. Caminada, "Ecotoxicology of human pharmaceuticals," *Aquat. Toxicol.*, vol. 76, no. 2, pp. 122–159, 2006.
[16] T. A. Ternes, "Occurrence of drugs in German sewage treatment plants and rivers," *Water Res.*, vol. 32, no. 11, pp. 3245–3260, 1998.
[17] J. L. Wilkinson, A. B. A. Boxall, D. W. Kolpin, K. M. Y. Leung, R. W. S. Lai, C. G. Galban-Malagon, A. D. Adell, J. M. Mondon, M. Metian, R. A. Marchant, A. Bouwman, A. Wiegel, F. Wagner, and W. Giger, "Pharmaceutical pollution of the world's rivers," *Proc. Natl. Acad. Sci. USA*, vol. 119, no. 8, p. e2113947119, 2022.
[18] B. C. Tran, J. L. Tejeda, and B. W. Brooks, "Antidepressants in aquatic ecosystems: A global perspective," *Environ. Toxicol. Chem.*, vol. 39, no. 1, pp. 26–49, 2020.
[19] R. Loos, G. Locoro, S. Comero, S. Contini, D. Schwesig, F. Werres, P. Balsaa, O. Gans, S. Weiss, L. Blaha, M. Bolchi, and B. M. Gawlik, "Pan-European survey on the occurrence of selected polar organic persistent pollutants in ground water," *Water Res.*, vol. 44, no. 14, pp. 4115–4126, 2010.
[20] D. J. Caldwell, F. Mastrocco, T. H. Hutchinson, R. Länge, D. Heijerick, C. R. Janssen, P. D. Anderson, and J. P. Sumpter, "Derivation of an aquatic predicted no-effect concentration for the synthetic hormone, 17α-ethinyl estradiol," *Environ. Sci. Technol.*, vol. 42, no. 19, pp. 7046–7054, 2008.
[21] T. A. Ternes, J. Stumpf, J. Müller, K. Haberer, R. D. Wilken, and M. Servos, "Behavior and occurrence of estrogens in municipal sewage treatment plants," *Sci. Total Environ.*, vol. 225, no. 1–2, pp. 81–90, 1999.
[22] A. B. A. Boxall, M. A. Rudd, B. W. Brooks, D. J. Caldwell, K. Choi, S. Hickmann, E. Innes, K. Ostapyk, J. P. Staveley, T. Verslycke, G. T. Ankley, K. F. Beazley, S. E. Belanger, J. P. Berninger, P. Carriquiriborde, A. Coors, P. C. DeLeo, S. D. Dyer, J. F. Ericson, F. Gagné, J. P. Giesy, T. Gouin, L. Hallstrom, M. V. Karlsson, D. J. Larsson, J. M. Lazorchak, F. Mastrocco, A. McLaughlin, M. E. McMaster, R. D. Meyerhoff, R. Moore, J. L. Parrott, J. R. Snape, R. Murray-Smith, M. R. Servos, P. K. Sibley, J. O. Straub, N. D. Szabo, E. Topp, G. R. Tetreault, V. L. Trudeau, and G. Van Der Kraak, "Pharmaceuticals and personal care products in the environment: What are the big questions?" *Environ. Health Perspect.*, vol. 120, no. 9, pp. 1221–1229, 2012.
[23] M. Gros, M. Petrovic, A. Ginebreda, and D. Barcelo, "Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes," *Environ. Int.*, vol. 36, no. 1, pp. 15–26, 2010.
[24] R. Loos, B. M. Gawlik, G. Locoro, E. Rimaviciute, S. Contini, and G. Bidoglio, "EU-wide survey of polar organic persistent pollutants in European river waters," *Environ. Pollut.*, vol. 157, no. 2, pp. 561–568, 2009.
[25] Y. Zhang, S. U. Geißen, and C. Gal, "Carbamazepine and diclofenac: Removal in wastewater treatment plants and occurrence in water bodies," *Chemosphere*, vol. 73, no. 8, pp. 1151–1161, 2008.
[26] S. D. Richardson and T. A. Ternes, "Water analysis: Emerging contaminants and current issues," *Anal. Chem.*, vol. 90, no. 1, pp. 398–428, 2018.
[27] J. Margot, C. Kienle, A. Magnet, M. Weil, L. Rossi, L. F. de Alencastro, C. Abegglen, D. Thonney, N. Chèvre, M. Schärer, and D. A. Barry, "Treatment of micropollutants in municipal wastewater: Ozone or powdered activated carbon?" *Sci. Total Environ.*, vol. 461–462, pp. 480–498, 2013.
[28] A. K. Sarmah, M. T. Meyer, and A. B. A. Boxall, "A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment," *Chemosphere*, vol. 65, no. 5, pp. 725–759, 2006.
[29] T. Christian, R. J. Schneider, H. A. Farber, D. Skutlarek, M. T. Meyer, and H. E. Goldbach, "Determination of antibiotic residues in manure, soil, and surface waters," *Acta Hydrochim. Hydrobiol.*, vol. 31, no. 1, pp. 36–44, 2003.
[30] W. C. Li, "Occurrence, sources, and fate of pharmaceuticals in aquatic environment and soil," *Environ. Pollut.*, vol. 187, pp. 193–201, 2014.
[31] F. C. Cabello, "Heavy use of prophylactic antibiotics in aquaculture: A growing problem for human and animal health and for the environment," *Environ. Microbiol.*, vol. 8, no. 7, pp. 1137–1144, 2006.
[32] D. G. J. Larsson, C. de Pedro, and N. Paxeus, "Effluent from drug manufactures contains extremely high levels of pharmaceuticals," *J. Hazard. Mater.*, vol. 148, no. 3, pp. 751–755, 2007.
[33] A. L. Batt, I. B. Bruce, and D. S. Aga, "Evaluating the vulnerability of surface waters to antibiotic contamination from varying wastewater treatment plant discharges," *Environ. Pollut.*, vol. 142, no. 2, pp. 295–302, 2006.

[34] K. Kümmerer and A. Henninger, "Promoting resistance by the emission of antibiotics from hospitals and households into effluent," *Clin. Microbiol. Infect.*, vol. 9, no. 12, pp. 1203–1214, 2003.
[35] T. Bound and N. Voulvoulis, "Household disposal of pharmaceuticals as a pathway for aquatic contamination in the United Kingdom," *Environ. Health Perspect.*, vol. 113, no. 12, pp. 1705–1711, 2005.
[36] J. Fick, H. Söderström, R. H. Lindberg, C. Phan, M. Tysklind, and D. G. J. Larsson, "Contamination of surface, ground, and drinking water from pharmaceutical production," *Environ. Toxicol. Chem.*, vol. 28, no. 12, pp. 2522–2527, 2009.
[37] S. L. Bartelt-Hunt, D. D. Snow, T. Damon, J. Quinn, and M. T. Meyer, "The occurrence of illicit and therapeutic pharmaceuticals in wastewater effluent and surface waters in Nebraska," *Environ. Pollut.*, vol. 157, no. 3, pp. 786–791, 2009.
[38] B. Du, A. G. Price, W. J. Scott, L. A. Kristofco, A. J. Ramirez, C. K. Chambliss, J. C. Yelderman, and B. W. Brooks, "Comparison of contaminants of emerging concern removal, discharge, and water quality hazards among centralized and on-site wastewater treatment system effluents receiving common wastewater influent," *Sci. Total Environ.*, vol. 466–467, pp. 976–984, 2014.
[39] R. F. Shore, M. A. Taggart, J. Smits, R. Mateo, N. B. Richards, and S. Burgar, "Detection of pharmaceuticals in wildlife: A review," *Environ. Pollut.*, vol. 194, pp. 145–154, 2014.
[40] Z. Li, H. Hong, L. Liao, C. J. Ackley, L. A. MacDonald, R. J. Bartlett, and S. M. Emard, "Microplastics as vectors for environmental contaminants: Exploring sorption, desorption, and transfer to biota," *Sci. Total Environ.*, vol. 720, p. 137478, 2020.
[41] M. B. Ahmed, J. L. Zhou, H. H. Ngo, W. Guo, M. Thomaidis, and J. Xu, "Progress in the biological and chemical treatment technologies for emerging contaminant removal from wastewater: A critical review," *J. Hazard. Mater.*, vol. 323, pp. 274–298, 2017.
[42] C. G. Pan and G. G. Ying, "Sorption of antibiotics to soil and sediment: A review," *Environ. Pollut.*, vol. 191, pp. 131–144, 2014.
[43] J. Tolls, "Sorption of veterinary pharmaceuticals in soils: A review," *Environ. Sci. Technol.*, vol. 35, no. 17, pp. 3397–3406, 2001.
[44] A. K. Thomsen, M. C. Carter, and H. E. Allen, "Sorption of fluoroquinolone antibiotics to sediments," *Chemosphere*, vol. 61, no. 1, pp. 128–134, 2005.
[45] B. J. Reid, K. C. Jones, and K. T. Semple, "Bioavailability of persistent organic pollutants in soils and sediments—A perspective on mechanisms, consequences and assessment," *Environ. Pollut.*, vol. 108, no. 1, pp. 103–112, 2000.
[46] M. L. Vasquez, M. B. Lamb, and J. J. Macalady, "Sorption of ciprofloxacin to river sediments," *Environ. Sci. Technol.*, vol. 46, no. 6, pp. 3342–3349, 2012.
[47] B. Nowack and J. M. VanBriesen, "Chelating agents in the environment," *Biogeochemistry*, vol. 73, no. 1, pp. 1–6, 2005.
[48] K. Kümmerer, "The presence of pharmaceuticals in the environment due to human use—Present knowledge and future challenges," *J. Environ. Manage.*, vol. 90, no. 8, pp. 2354–2366, 2009.
[49] R. H. Lindberg, P. Wennberg, M. I. Johansson, M. Tysklind, and B. Andersson, "Screening of human pharmaceuticals in the aquatic environment," *Environ. Sci. Technol.*, vol. 39, no. 10, pp. 3421–3429, 2005.
[50] T. E. Felix-Cañedo, J. C. Durán-Álvarez, and B. Jiménez-Cisneros, "The occurrence and distribution of a group of organic micropollutants in Mexico City's water sources," *Sci. Total Environ.*, vol. 444, pp. 96–104, 2013.
[51] J. J. Buerge, T. Poiger, M. D. Müller, and H. R. Buser, "Combined sewer overflows to surface waters detected by the anthropogenic marker caffeine," *Environ. Sci. Technol.*, vol. 40, no. 13, pp. 4096–4102, 2006.
[52] J. L. Oaks, M. Gilbert, M. Z. Virani, R. T. Watson, C. U. Meteyer, B. A. Rideout, H. L. Shivaprasad, S. Ahmed, M. J. I. Chaudhry, M. Arshad, S. Mahmood, A. Ali, and A. A. Khan, "Diclofenac residues as the cause of vulture population decline in Pakistan," *Nature*, vol. 427, no. 6975, pp. 630–633, 2004.
[53] T. A. Ternes, P. Kreckel, and J. Mueller, "Behaviour and occurrence of estrogens in municipal sewage treatment plants—II. Aerobic batch experiments with activated sludge," *Sci. Total Environ.*, vol. 225, no. 1–2, pp. 91–99, 1999.
[54] M. Meredith-Williams, L. J. Carter, R. Fussell, D. Raffaelli, R. Ashauer, and A. B. A. Boxall, "Uptake and depuration of pharmaceuticals in aquatic invertebrates," *Environ. Pollut.*, vol. 165, pp. 250–258, 2012.
[55] A. M. Grabicova, R. H. Lindberg, M. Östman, R. Grabic, T. Randak, D. G. J. Larsson, and J. Fick, "Tissue-specific bioconcentration of antidepressants in fish exposed to effluent from a municipal sewage treatment plant," *Sci. Total Environ.*, vol. 487, pp. 783–790, 2014.
[56] B. W. Brooks, C. K. Chambliss, J. K. Stanley, A. Ramirez, K. E. Banks, R. D. Johnson, and R. J. Lewis, "Determination of select antidepressants in fish from an effluent-dominated stream," *Environ. Toxicol. Chem.*, vol. 24, no. 10, pp. 464–469, 2005.
[57] D. J. Fort, D. J. Mathis, K. R. Pawlowski, and M. L. Wolf, "Bioaccumulation and biotransformation of pharmaceuticals in aquatic organisms," *Environ. Toxicol. Chem.*, vol. 33, no. 7, pp. 1461–1468, 2014.
[58] K. A. Kidd, P. J. Blanchfield, K. H. Mills, V. P. Palace, R. E. Evans, J. M. Lazorchak, and F. W. Yost, "Collapse of a fish population after exposure to a synthetic estrogen," *Proc. Natl. Acad. Sci. USA*, vol. 104, no. 21, pp. 8897–8901, 2007.
[59] M. Schriks, M. B. Heringa, M. M. E. van der Kooi, P. de Voogt, and A. P. van Wezel, "Toxicological relevance of emerging contaminants for drinking water quality," *Water Res.*, vol. 44, no. 2, pp. 461–476, 2010.
[60] M. A. Borowitzka, "Microalgae as sources of pharmaceuticals and other biologically active compounds," *J. Appl. Phycol.*, vol. 7, no. 1, pp. 3–15, 1995.
[61] S. A. Snyder, "Occurrence, treatment, and toxicological relevance of EDCs and pharmaceuticals in water," *Ozone Sci. Eng.*, vol. 30, no. 1, pp. 65–69, 2008.
[62] E. M. Thurman and M. T. Meyer, "The occurrence of antibiotics in groundwater and surface water," *J. Am. Water Works Assoc.*, vol. 92, no. 4, pp. 102–114, 2000.
[63] J. C. Chee-Sanford, R. I. Aminov, I. J. Krapac, N. Garrigues-Jeanjean, and R. I. Mackie, "Occurrence and diversity of tetracycline resistance genes in lagoons and groundwater underlying two swine production facilities," *Appl. Environ. Microbiol.*, vol. 67, no. 4, pp. 1494–1502, 2001.

[64] J. L. Balcázar, J. Subirats, and C. M. Borrego, "The role of biofilms as environmental reservoirs of antibiotic resistance," *Front. Microbiol.*, vol. 6, p. 1216, 2015.
[65] J. Q. Xiong, M. B. Kurade, and B. H. Jeon, "Biodegradation of levofloxacin by an acclimated freshwater microalga, Chlorella vulgaris," *Chem. Eng. J.*, vol. 313, pp. 1251–1257, 2017.
[66] M. C. Dodd, "Potential impacts of disinfection processes on the formation of antibiotic-resistant bacteria," *Curr. Opin. Biotechnol.*, vol. 23, no. 4, pp. 561–567, 2012.
[67] J. Bengtsson-Palme, E. Kristiansson, and D. G. J. Larsson, "Environmental factors influencing the development and spread of antibiotic resistance," *FEMS Microbiol. Rev.*, vol. 42, no. 1, pp. 68–80, 2018.
[68] R. Pei, J. Kim, B. J. Latshaw, and J. J. F. McConnell, "Antibiotic resistance in aquatic environments: A review," *Environ. Int.*, vol. 34, no. 8, pp. 1213–1222, 2008.
[69] S. Jobling, M. Nolan, C. R. Tyler, G. Brighty, and J. P. Sumpter, "Widespread sexual disruption in wild fish," *Environ. Sci. Technol.*, vol. 32, no. 17, pp. 2498–2506, 1998.
[70] T. Colborn, F. S. vom Saal, and A. M. Soto, "Developmental effects of endocrine-disrupting chemicals in wildlife and humans," *Environ. Health Perspect.*, vol. 101, no. 5, pp. 378–384, 1993.
[71] L. H. Santos, A. N. Araújo, A. Fachini, A. Pena, C. Delerue-Matos, and M. C. B. S. M. Montenegro, "Ecotoxicological aspects related to the presence of pharmaceuticals in the aquatic environment," *J. Hazard. Mater.*, vol. 175, no. 1–3, pp. 45–95, 2010.
[72] E. D. De Lange, W. H. J. Vaes, and J. L. M. Hermens, "QSARs for toxicity of pharmaceuticals to aquatic organisms," *Environ. Toxicol. Chem.*, vol. 28, no. 6, pp. 1137–1146, 2009.
[73] B. Halling-Sørensen, "Algal toxicity of antibacterial agents used in intensive farming," *Chemosphere*, vol. 40, no. 7, pp. 731–739, 2000.
[74] R. Altenburger, S. Ait-Aissa, P. Antczak, T. Backhaus, D. Barceló, T. B. Seiler, F. Brion, W. Busch, K. Chipman, M. L. de Alda, G. de Aragão Umbuzeiro, B. I. Escher, F. Falciani, M. Faust, A. Focks, K. Hilscherova, J. Hollert, S. Jager, A. Jahnke, A. Kortenkamp, M. Krauss, G. F. Lemkau, P. Lettieri, S. Leusch, S. Liu, P. Lopez, S. Loureiro, A. Miller, P. Molander, J. L. Muñoz, M. Neumann, S. Ovari, M. Ocampo-Duque, P. Pandard, L. Patureau, M. Röder, C. Roux, M. Schriks, N. Schwienbacher, T. Seiler, H. Serra, H. Tang, W. H. van der Burg, B. van der Grinten, A. Werner, C. Wheeler, J. R. Zwart, and M. Krauss, "Future water quality monitoring—Adapting tools to deal with mixtures of pollutants in water resource management," *Sci. Total Environ.*, vol. 512–513, pp. 540–551, 2015.
[75] M. Cleuvers, "Mixture toxicity of the anti-inflammatory drugs diclofenac, ibuprofen, naproxen, and acetylsalicylic acid," *Ecotoxicol. Environ. Saf.*, vol. 59, no. 3, pp. 309–315, 2004.
[76] A. Pruden, R. Pei, H. Storteboom, and K. H. Carlson, "Antibiotic resistance genes as emerging contaminants: Studies in northern Colorado," *Environ. Sci. Technol.*, vol. 40, no. 23, pp. 7445–7450, 2006.
[77] E. Marti, J. Jofre, and J. L. Balcázar, "Prevalence of antibiotic resistance genes and bacterial community composition in a river influenced by a wastewater treatment plant," *PLoS ONE*, vol. 8, no. 10, p. e78906, 2013.
[78] T. U. Berendonk, C. M. Manaia, C. Merlin, D. Fatta-Kassinos, E. Cytryn, F. Walsh, H. Bürgmann, H. Sørum, M. Norström, M. Pons, N. Kreuzinger, P. Huovinen, S. Stefani, T. Schwartz, V. Kisand, J. L. Martinez, and J. L. Balcázar, "Tackling antibiotic resistance: The environmental framework," *Nat. Rev. Microbiol.*, vol. 13, no. 5, pp. 310–317, 2015.
[79] M. A. Gray, A. J. Trimble, and G. R. Latchford, "Effects of pharmaceuticals on aquatic invertebrates: A review," *Environ. Toxicol. Chem.*, vol. 31, no. 10, pp. 2404–2417, 2012.
[80] S. K. Behera, H. W. Kim, J. E. Oh, and H. S. Park, "Occurrence and removal of antibiotics, hormones and several other pharmaceuticals in wastewater treatment plants of the largest industrial city of Korea," *Sci. Total Environ.*, vol. 409, no. 20, pp. 4351–4360, 2011.
[81] A. Zenker, M. C. Cicero, F. Prestinaci, P. Bottoni, and M. Carere, "Bioaccumulation and biomagnification potential of pharmaceuticals with a focus to the aquatic environment," *J. Environ. Manage.*, vol. 133, pp. 378–387, 2014.
[82] M. H. Depledge, "Pharmaceuticals in the environment: An overview of the science," *Environ. Toxicol. Chem.*, vol. 33, no. 7, pp. 1429–1430, 2014.
[83] E. N. Evgenidou, I. K. Konstantinou, and D. A. Lambropoulou, "Occurrence and removal of transformation products of PPCPs and illicit drugs in wastewaters: A review," *Sci. Total Environ.*, vol. 505, pp. 905–926, 2015.
[84] A. J. Ramirez, R. A. Brain, S. Usenko, M. A. Mottaleb, J. G. O'Donnell, L. L. Stahl, J. B. Wathen, B. D. Snyder, J. L. Pitt, P. Perez-Hurtado, L. L. Dobbins, B. W. Brooks, and C. K. Chambliss, "Occurrence of pharmaceuticals and personal care products in fish: Results of a national pilot study in the United States," *Environ. Toxicol. Chem.*, vol. 28, no. 12, pp. 2587–2597, 2009.
[85] B. Subedi, B. Du, C. K. Chambliss, J. Koschorreck, U. Rüdel, M. Rüßmann, M. Schäfer, M. Spycher, J. Hollender, and B. W. Brooks, "Occurrence of pharmaceuticals and personal care products in German fish tissue: A national study," *Environ. Sci. Technol.*, vol. 46, no. 16, pp. 9047–9054, 2012.
[86] M. J. Focazio, D. W. Kolpin, K. K. Barnes, E. T. Furlong, M. T. Meyer, S. D. Zaugg, L. B. Barber, and E. M. Thurman, "A national reconnaissance for pharmaceuticals and other organic wastewater contaminants in the United States—II) Untreated drinking water sources," *Sci. Total Environ.*, vol. 402, no. 2–3, pp. 201–216, 2008.
[87] P. E. Stackelberg, E. T. Furlong, M. T. Meyer, S. D. Zaugg, A. K. Henderson, and D. B. Reissman, "Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water-treatment plant," *Sci. Total Environ.*, vol. 329, no. 1–3, pp. 99–113, 2004.
[88] R. J. C. A. Steen, P. E. G. Leonards, U. A. T. Brinkman, D. Barceló, J. Tronczynski, S. Albanis, and T. A. Ternes, "Ecological hazard assessment of pharmaceuticals in European waters," *Environ. Sci. Technol.*, vol. 33, no. 15, pp. 2529–2536, 1999.

[89] M. Launay, Y. Dittmer, and H. Steinmetz, "Organic micropollutants discharged by combined sewer overflows—Characterisation of pollutant sources and stormwater-related processes," *Water Res.*, vol. 104, pp. 82–92, 2016.
[90] R. H. Lindberg, U. Olofsson, P. Rendahl, M. I. Johansson, M. Tysklind, and B. A. Andersson, "Behavior of fluoroquinolones and trimethoprim during mechanical, chemical, and active sludge treatment of sewage water and digestion of sludge," *Environ. Sci. Technol.*, vol. 40, no. 3, pp. 1042–1048, 2006.
[91] A. Göbel, C. S. McArdell, A. Joss, H. Siegrist, and W. Giger, "Fate of sulfonamides, macrolides, and trimethoprim in different wastewater treatment technologies," *Sci. Total Environ.*, vol. 372, no. 2–3, pp. 361–371, 2007.
[92] D. W. Kolpin, E. T. Furlong, M. T. Meyer, E. M. Thurman, S. D. Zaugg, L. B. Barber, and H. T. Buxton, "Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: A national reconnaissance," *Environ. Sci. Technol.*, vol. 36, no. 6, pp. 1202–1211, 2002.
[93] V. Burke, J. Greskowiak, T. Asmuß, R. Bremermann, T. Taute, and G. Massmann, "Temperature dependent redox zonation and attenuation of wastewater-derived organic micropollutants in the hyporheic zone," *Sci. Total Environ.*, vol. 482–483, pp. 53–61, 2014.
[94] M. L. Hladik, E. T. Furlong, D. R. Helsel, J. L. Gray, D. W. Kolpin, L. B. Barber, S. D. Zaugg, and M. T. Meyer, "Persistence of pharmaceutical compounds in lake sediments," *Environ. Sci. Technol.*, vol. 48, no. 13, pp. 7406–7414, 2014.
[95] J. L. Loizeau, L. Arbouille, S. Santiago, and C. R. Mori, "The occurrence of pharmaceutical residues in Lake Geneva," *Arch. Sci.*, vol. 55, pp. 65–76, 2002.
[96] V. Matamoros and J. M. Bayona, "Elimination of pharmaceuticals and personal care products in subsurface flow constructed wetlands," *Environ. Sci. Technol.*, vol. 40, no. 18, pp. 5811–5816, 2006.
[97] L. D. Nghiem, A. I. Schäfer, and M. Elimelech, "Pharmaceutical retention mechanisms by nanofiltration membranes," *Environ. Sci. Technol.*, vol. 39, no. 19, pp. 7698–7705, 2005.
[98] B. M. Gawlik, S. Platzer-Schneider, N. Kreuzinger, T. Knopp, and R. Loos, "Pharmaceuticals in the Baltic Sea: Inputs, occurrence, and fate," *Mar. Pollut. Bull.*, vol. 106, no. 1–2, pp. 16–23, 2016.
[99] J. L. Tambosi, L. Y. Yamanaka, H. J. José, and R. F. P. M. Moreira, "Recent research data on the removal of pharmaceuticals from sewage treatment plants (STP)," *Quím. Nova*, vol. 33, no. 2, pp. 411–420, 2010.
[100] Y. Luo, W. Guo, H. H. Ngo, L. D. Nghiem, F. I. Hai, J. Zhang, S. Liang, and X. C. Wang, "A review on the occurrence of micropollutants in the aquatic environment and their fate and removal during wastewater treatment," *Sci. Total Environ.*, vol. 473–474, pp. 619–641, 2014.
[101] M. Gonzalez-Rey and M. J. Bebianno, "Does selective serotonin reuptake inhibitor (SSRI) fluoxetine affect mussel Mytilus galloprovincialis?" *Environ. Pollut.*, vol. 173, pp. 200–209, 2013.
[102] S. C. Monteiro and A. B. A. Boxall, "Occurrence and fate of human pharmaceuticals in the environment," *Rev. Environ. Contam. Toxicol.*, vol. 202, pp. 53–154, 2010.
[103] D. G. J. Larsson, "Antibiotics in the environment," *Ups. J. Med. Sci.*, vol. 119, no. 2, pp. 108–112, 2014.
[104] M. Zuccato, D. Calamari, M. Natangelo, R. Fanelli, and R. Bagnati, "Presence of pharmaceutical compounds in surface waters of the Po River Basin, Italy," *Environ. Int.*, vol. 26, no. 5–6, pp. 387–392, 2001.
[105] A. Pal, K. Y. H. Gin, A. Y. C. Lin, and M. Reinhard, "Impacts of emerging organic contaminants on freshwater resources: Review of recent occurrences, sources, fate and effects," *Sci. Total Environ.*, vol. 408, no. 24, pp. 6062–6069, 2010.
[106] J. Hollender, B. I. Escher, Y. S. Peek, Y. Lee, S. D. Kim, and W. Giger, "Elimination of organic micropollutants in a municipal wastewater treatment plant upgraded with a full-scale post-ozonation followed by sand filtration," *Environ. Sci. Technol.*, vol. 43, no. 20, pp. 7862–7869, 2009.
[107] M. M. Huber, S. Canonica, G. Y. Park, and U. von Gunten, "Oxidation of pharmaceuticals during ozonation and advanced oxidation processes," *Environ. Sci. Technol.*, vol. 37, no. 5, pp. 1016–1024, 2003.
[108] S. A. Snyder, S. Adham, A. M. Redding, F. S. Cannon, J. DeCarolis, W. T. Oppenheimer, E. C. Wert, and Y. Yoon, "Role of membranes and activated carbon in the removal of endocrine disruptors and pharmaceuticals," *Desalination*, vol. 202, no. 1–3, pp. 156–181, 2007.
[109] J. Radjenović, M. Petrović, F. Ventura, and D. Barceló, "Rejection of pharmaceuticals in nanofiltration and reverse osmosis membrane drinking water treatment," *Water Res.*, vol. 42, no. 14, pp. 3601–3610, 2008.
[110] R. S. Yeh, T. J. G. Luntz, and J. L. Schnoor, "Enzymatic degradation of pharmaceuticals in the environment," *Environ. Sci. Technol.*, vol. 44, no. 19, pp. 7578–7585, 2010.
[111] T. Eggen, M. Moeder, and A. Arukwe, "Municipal landfill leachates: A significant source for new and emerging pollutants," *Sci. Total Environ.*, vol. 408, no. 21, pp. 5147–5157, 2010.
[112] European Commission, "Directive 2000/60/EC of the European Parliament and of the Council establishing a framework for Community action in the field of water policy," *Off. J. Eur. Communities*, vol. L327, pp. 1–73, 2000.
[113] M. Stuart, D. Lapworth, E. Crane, and A. Hart, "Review of risk from potential emerging contaminants in UK groundwater," *Sci. Total Environ.*, vol. 416, pp. 1–21, 2012.
[114] U.S. Environmental Protection Agency, "Contaminant Candidate List 3—CCL 3," Federal Register, vol. 74, no. 194, pp. 51850–51862, 2009.
[115] M. Carere, S. Polesello, C. Kase, and B. M. Gawlik, "The emerging contaminants in the context of the EU Water Framework Directive," in *Emerging Contaminants in River Ecosystems*, M. Petrovic, S. Sabater, A. Elosegi, and D. Barceló, Eds. Cham, Switzerland: Springer, 2016, pp. 197–215.
[116] T. P. Halappa Gowda and R. D. Lock, "Public–private partnerships for addressing pharmaceutical pollution," *J. Environ. Manage.*, vol. 255, p. 109770, 2020.

[117] K. Kümmerer, "Green and sustainable pharmacy," in *Green and Sustainable Pharmacy*, K. Kümmerer and M. Hempel, Eds. Berlin, Germany: Springer, 2010, pp. 1–10.
[118] C. G. Daughton, "Cradle-to-cradle stewardship of drugs for minimizing their environmental disposition while promoting human health," *Environ. Health Perspect.*, vol. 111, no. 5, pp. 757–774, 2003.
[119] A. L. N. van Nuijs, A. Covaci, J. Beyers, A. Gheorghe, P. G. Jorens, H. Neels, and A. L. N. van Nuijs, "Occurrence of pharmaceuticals in the environment: The importance of non-target analysis," *Anal. Bioanal. Chem.*, vol. 398, no. 6, pp. 2211–2217, 2010.
[120] M. H. Depledge and R. Barrett, "Reducing the environmental impact of pharmaceuticals," *Sustainable Chem. Pharm.*, vol. 1, pp. 1–2, 2015.
[121] D. J. Lapworth, N. Baran, M. E. Stuart, and R. S. Ward, "Emerging organic contaminants in groundwater: A review of sources, fate and occurrence," *Environ. Pollut.*, vol. 163, pp. 287–303, 2012.
[122] D. Mackay and L. A. Burns, "Application of fugacity models to the environmental fate of chemicals," *Environ. Sci. Technol.*, vol. 29, no. 1, pp. 13–21, 1995.
[123] M. Schaffer, A. Börnick, E. Nödler, K. Licha, and T. Worch, "Modeling the fate of pharmaceuticals in rivers using a multimedia model," *Environ. Model. Softw.*, vol. 77, pp. 112–123, 2016.
[124] P. J. Phillips, S. D. Smith, D. W. Kolpin, S. D. Zaugg, H. T. Buxton, E. T. Furlong, K. Esposito, and B. Stinson, "Pharmaceutical formulation facilities as sources of pharmaceuticals to municipal wastewater treatment plants," *Sci. Total Environ.*, vol. 408, no. 13, pp. 2711–2718, 2010.
[125] M. A. Rudd, G. T. Ankley, R. V. Blazej, B. W. Brooks, K. D. Denslow, J. P. Giesy, L. J. Gray, J. M. Lazorchak, M. R. Milsk, and B. O. Clarke, "A framework for assessing the ecological risks of pharmaceuticals in the environment," *Environ. Toxicol. Chem.*, vol. 33, no. 9, pp. 1931–1939, 2014.
[126] E. Archer, B. Petrie, B. Kasprzyk-Hordern, and G. M. Wolfaardt, "The fate of pharmaceuticals and personal care products (PPCPs), endocrine disrupting contaminants (EDCs), metabolites and illicit drugs in a WWTW and environmental waters," *Chemosphere*, vol. 174, pp. 437–446, 2017.
[127] T. aus der Beek, F. A. Weber, A. Bergmann, S. Hickmann, I. Ebert, A. Hein, and A. Küster, "Pharmaceuticals in the environment—Global occurrences and perspectives," *Environ. Toxicol. Chem.*, vol. 35, no. 4, pp. 823–835, 2016.
[128] J. Corcoran, M. J. Winter, and C. R. Tyler, "Pharmaceuticals in the aquatic environment: A critical review of the evidence for health effects in fish," *Crit. Rev. Toxicol.*, vol. 40, no. 4, pp. 287–304, 2010.
[129] M. Celander, J. V. Goldstone, and J. J. Stegeman, "Effects of pharmaceuticals on cytochrome P450 expression in fish: A review," *Aquat. Toxicol.*, vol. 101, no. 1, pp. 1–13, 2011.
[130] M. O. Barbosa, N. F. F. Moreira, A. R. Ribeiro, M. F. R. Pereira, and A. M. T. Silva, "Occurrence and removal of organic micropollutants: An overview of the watch list of EU Decision 2015/495," *Water Res.*, vol. 94, pp. 257–279, 2016.
[131] C. G. Daughton and T. A. Ternes, "Pharmaceuticals and personal care products in the environment: Agents of subtle change?" *Environ. Health Perspect.*, vol. 107, no. Suppl 6, pp. 907–938, 1999.
[132] P. Verlicchi, M. Al Aukidy, and A. Galletti, "Hospital effluent: Investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment," *Sci. Total Environ.*, vol. 430, pp. 109–118, 2012.
[133] B. Roig, "Pharmaceuticals in the environment: Current knowledge and future challenges," *Environ. Chem. Lett.*, vol. 8, no. 1, pp. 1–2, 2010.